Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Like
Tweet
Print
Magalie Emilebacker
Moderna, Inc.
Poster(s):
(128) Safety of Moderna mRNA-1273.214 and mRNA-1273.222 COVID-19 bivalent vaccines: results from post-marketing surveillance in South Korea
Monday, August 26, 2024
8:00 AM – 6:00 PM
CEST
(337) Defining a Post-vaccine Myocarditis Cohort by Applying CDC Case Definition to Structured EHR and Claims Data as a Proxy for Case Adjudication
Tuesday, August 27, 2024
8:00 AM – 6:00 PM
CEST
(367) VAC4EU study to identify risk factors and characterize the clinical course of myocarditis/pericarditis following mRNA-1273 vaccination in four European countries: first descriptive analyses
Tuesday, August 27, 2024
8:00 AM – 6:00 PM
CEST
